跳至主要内容
临床试验/NL-OMON47173
NL-OMON47173已完成不适用

The role of glutamate in cognition in adults with chromosome 22q11 deletion syndrome - Glutamate and cognition in adults with 22q11DS

niversiteit Maastricht0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • For participants with 22q11DS:
  • Confirmed diagnosis of 22q11DS established by FISH, microarray or MLPA analysis.
  • Age 18 and older and mentally competent to give informed consent.
  • No psychopharmacological treatment at the time of inclusion .
  • No presence of a physical/medical condition that may interfere with the study.
  • No contraindication for MRI;For healthy controls:
  • Healthy subjects will be matched for age, gender and ethnicity.
  • No use of any psychopharmacological treatment at the time of inclusion.
  • No presence of a physical/medical condition that may interfere with the study.
  • No contraindication for MRI

排除标准

  • For participants with 22q11DS:
  • Other chromosomal abnormalities
  • Current substance abuse / dependence
  • Comorbid psychiatric / neurologic disorder
  • Contraindications for Riluzole;For healthy controls:
  • Any chromosomal abnormalities
  • Current substance abuse / dependence
  • A psychiatric or neurologic disorder
  • Contraindications for riluzole

研究者

相似试验